237 related articles for article (PubMed ID: 29206892)
1. Progestin-associated shift of meningioma mutational landscape.
Peyre M; Gaillard S; de Marcellus C; Giry M; Bielle F; Villa C; Boch AL; Loiseau H; Baussart B; Cazabat L; Raffin-Sanson ML; Sanson M; Kalamarides M
Ann Oncol; 2018 Mar; 29(3):681-686. PubMed ID: 29206892
[TBL] [Abstract][Full Text] [Related]
2. Preliminary report of patients with meningiomas exposed to Cyproterone Acetate, Nomegestrol Acetate and Chlormadinone Acetate - Monocentric ongoing study on progestin related meningiomas.
Devalckeneer A; Aboukais R; Bourgeois P; De Witte O; Racape J; Caron S; Perbet R; Maurage CA; Lejeune JP
Clin Neurol Neurosurg; 2021 Nov; 210():106959. PubMed ID: 34592677
[TBL] [Abstract][Full Text] [Related]
3. Respective roles of Pik3ca mutations and cyproterone acetate impregnation in mouse meningioma tumorigenesis.
Cômes PC; Le Van T; Tran S; Huard S; Abi-Jaoude S; Venot Q; Marijon P; Boetto J; Blouin A; Bielle F; Ducos Y; Teranishi Y; Kalamarides M; Peyre M
Cancer Gene Ther; 2023 Aug; 30(8):1114-1123. PubMed ID: 37188724
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
[TBL] [Abstract][Full Text] [Related]
5. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
6. Atypical evolution of meningiomatosis after discontinuation of cyproterone acetate: clinical cases and histomolecular characterization.
Passeri T; Giammattei L; Le Van T; Abbritti R; Perrier A; Wong J; Bourneix C; Polivka M; Adle-Biassette H; Bernat AL; Masliah-Planchon J; Mandonnet E; Froelich S
Acta Neurochir (Wien); 2022 Jan; 164(1):255-263. PubMed ID: 34613529
[TBL] [Abstract][Full Text] [Related]
7. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
8. SWI/SNF chromatin remodeling complex alterations in meningioma.
Gill CM; Loewenstern J; Rutland JW; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Fowkes M; Shrivastava RK
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3431-3440. PubMed ID: 33715086
[TBL] [Abstract][Full Text] [Related]
9. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
[TBL] [Abstract][Full Text] [Related]
10. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
11. NF2 mutations in secretory and other rare variants of meningiomas.
Hartmann C; Sieberns J; Gehlhaar C; Simon M; Paulus W; von Deimling A
Brain Pathol; 2006 Jan; 16(1):15-9. PubMed ID: 16612978
[TBL] [Abstract][Full Text] [Related]
12. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
[TBL] [Abstract][Full Text] [Related]
13. Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas.
Apra C; Roblot P; Alkhayri A; Le Guérinel C; Polivka M; Chauvet D
J Neurooncol; 2020 Aug; 149(1):95-101. PubMed ID: 32705456
[TBL] [Abstract][Full Text] [Related]
14. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
[TBL] [Abstract][Full Text] [Related]
15. Unilateral vestibular schwannoma and meningiomas in a patient with PIK3CA-related segmental overgrowth: Co-occurrence of mosaicism for 2 rare disorders.
Mills JR; Moyer AM; Kipp BR; Poplawski AB; Messiaen LM; Babovic-Vuksanovic D
Clin Genet; 2018 Jan; 93(1):187-190. PubMed ID: 28737257
[TBL] [Abstract][Full Text] [Related]
16. Meningiomas in patients with long-term exposition to progestins: Characteristics and outcome.
Graillon T; Boissonneau S; Appay R; Boucekine M; Peyrière H; Meyer M; Farah K; Albarel F; Morange I; Castinetti F; Brue T; Fuentes S; Figarella-Branger D; Cuny T; Dufour H
Neurochirurgie; 2021 Nov; 67(6):556-563. PubMed ID: 33989642
[TBL] [Abstract][Full Text] [Related]
17. Opposed evolution of the osseous and soft parts of progestin-associated osteomeningioma after progestin intake discontinuation.
Florea SM; Passeri T; Abbritti R; Bernat AL; Fontanel S; Yoldjian I; Funck-Brentano T; Weill A; Mandonnet E; Froelich S
J Neurosurg; 2023 Oct; 139(4):944-952. PubMed ID: 36883659
[TBL] [Abstract][Full Text] [Related]
18. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
19. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.
Rutland JW; Gill CM; Loewenstern J; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Shrivastava RK; Fowkes M
Cancer Immunol Immunother; 2021 Jan; 70(1):169-176. PubMed ID: 32661686
[TBL] [Abstract][Full Text] [Related]
20. Sustained growth of intraosseous hormone-associated meningiomas after cessation of progestin therapy.
AbiJaoude S; Marijon P; Roblot P; Tran S; Cornu P; Kalamarides M; Peyre M
Acta Neurochir (Wien); 2021 Jun; 163(6):1705-1710. PubMed ID: 33649877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]